INTRODUCTION
The spleen is a highly structured lymphoid organ consisting of three main compartments: the red pulp (RP) where red blood cells are captured and recycled, the marginal zone (MZ) containing marginal zone B cells and phagocytes positioned along the marginal sinus, and the white pulp (WP) where the majority of T cells and B cells reside (Mebius and Kraal, 2005) . As microbes enter the marginal sinus of the spleen, they come in contact with a variety of splenic phagocytes, including macrophages, dendritic cells (DCs), and granulocytes (Kraal, 1992) . DCs play an important role in carrying antigen from peripheral tissues to draining lymph nodes to trigger the adaptive immune response (Angeli and Randolph, 2006) ; however, an analogous picture for how antigen transport and presentation takes place in the spleen is lacking. Experiments that use low-dose clodronate-liposome treatment to selectively deplete marginal zone macrophages (MZM) showed that these cells were not required for adaptive immunity to Listeria monocytogenes (Lm) (Aichele et al., 2003 ). An important role for DCs in immunity to Lm infection was more formally demonstrated via the CD11c-DTR system to deplete DCs (Jung et al., 2002; Muraille et al., 2005; Neuenhahn et al., 2006) . The issue of whether bacterial antigen transport to the periarteriolar lymphoid sheath (PALS) of the spleen is required for antigen presentation to T cells has been raised by others (Muraille et al., 2005; Kursar et al., 2005) but has not been investigated directly.
To investigate how antigen presentation occurs in the spleen, we used the Lm infection model. Lm is a Gram-positive intracellular bacterium widely used to study innate and adaptive immunity in mice (Mackaness, 1962; Pamer, 2004; Unanue, 1997) . After intravenous (i.v.) injection, Lm infects the liver and spleen, proliferates in these tissues for several days, and is eventually cleared by Lm-specific T cell responses. Mice that survive Lm challenge develop long-lasting CD8 + T cell immunity (Busch et al., 1998; Lauvau et al., 2001; Shedlock and Shen, 2003; Sun and Bevan, 2003) . Although T cell responses to Lm infection have been studied extensively, only recently has the impact of tissue structure on Lm pathogenesis and development of host responses been examined in situ (Khanna et al., 2007) . Here, we provide evidence that DCs in the spleen transport bacteria from the MZ to the PALS for antigen presentation to T cells, analogous to their role in carrying antigens from peripheral tissues to draining lymph nodes. As early as 9 hr after infection, we observed the clustering of Lm-specific T cells in the PALS by two-photon (2P) microscopy, indicating that antigen recognition occurs rapidly in the spleen. Preventing the entry of Lm into the PALS by pretreating mice with pertussis toxin (PTx) inhibited both the progression of Lm infection and the initiation of antigen presentation to CD8 + T cells.
RESULTS

PTx Treatment Inhibits Lm Entry into PALS
We quantitatively examined the tissue distribution of bacteria during splenic infection. Lm was injected i.v. into BALB/c mice, and at different times after infection, spleen cryosections were stained with antibodies to Lm and B220 and with phalloidin (Muraille et al., 2005) to identify the major spleen compartments ( Figure S1 available online). Lm redistributed dramatically from MZ and RP to the PALS over the first 24 hr of infection (Figures 1A and 1B) , consistent with previous histological studies (Conlan, 1996; Muraille et al., 2005) . Initially, bacteria were found primarily in the MZ ($65%) and RP ($30%) (2 hr, Figures 1A and  1C) . Lm was not observed in the PALS before 6 hr but was detected in low numbers at 9 hr and 12 hr (data not shown). After 24 hr, the distribution of Lm was reversed and the vast majority of bacteria were located in the PALS of the WP ($70%), with some bacteria ($20%) remaining in the MZ and RP (Figures 1B and 1C) . Soluble substances ($75 kD) can flow directly from the MZ into the white pulp through a conduit network (Mebius and Kraal, 2005) . Although bacteria are presumably too large to access the PALS via this conduit network, we examined the possibility that Lm might alter conduit permeability and flow directly into the WP to initiate PALS infection. First, we injected a large number of 1 mm fluorescent beads ($10 8 or 1000 times more than the Lm (C) Quantification of Lm distribution in the spleen at 0.5 hr (black bar) and 24 hr (white bar) after infection (10 pooled nonoverlapping images from 2 mice). The splenic compartments: RP, red pulp; MZ, marginal zone; B, B cell follicle; and PALS, T cell area were separated as described in Figure S1 .
(D and E) Spleen sections of PTx pretreated mice at 0.5 hr (D) and 24 hr (E) after infection. Scale bars represent 50 mm. Lower panels show magnified regions (white squares in upper panels).
(F) Lm distribution in the spleen of PTx-pretreated mice at 0.5 hr (black bar) and 24 hr (white bar) after infection (10 pooled nonoverlapping images from 2 mice).
(G) CFU per spleen in PTx-untreated mice (black bar) and PTx-pretreated mice (white bar) at 0.5 hr to 24 hr after infection with Lm (two separate experiments, n = 5 to 7 mice per group). The p value (0.0025) was calculated with a two-tailed MannWhitney U-test.
dose) and analyzed their distribution in the absence of infection. Beads were found exclusively in the MZ and RP at 2 hr and only a few entered the PALS at 24 hr ( Figures S2A and S2B ). Next we coinjected high molecular weight dextran and Lm to determine whether infection alters access to the WP ( Figure S2C ). Dextran remained outside the PALS 2 hr after coinjection with Lm, indicating that infection did not markedly affect conduit permeability over this time. We also injected 0.5 mm beads (approximately the diameter of Lm) 4 hr after infection and found that the beads localized to the MZ and RP and did not enter the PALS. Moreover, live Lm in the spleen is insensitive to the cell-impermeable antibiotic gentamicin within minutes of i.v. challenge ( Figure S2D ), suggesting that bacteria are intracellular and not free to enter the PALS independently.
We postulated that Lm entry into the PALS requires the migration of host cells. To test this hypothesis, we treated mice with 500 ng pertussis toxin (PTx) i.p. and then examined Lm tissue distribution at 0.5 and 24 hr after Lm challenge (Figures 1D and 1F) . PTx has been shown to block G protein-mediated (Gai) chemokine receptor signaling and to inhibit leukocyte trafficking (Ato et al., 2004; Huang et al., 2007; Itano et al., 2003; Okada and Cyster, 2007) . PTx treatment did not change the initial tissue distribution or the amount of Lm detected in spleen sections (Figures 1D and 1F) ; however, it profoundly inhibited Lm entry into the PALS ($99% decrease) 24 hr after challenge (Figures 1E and 1F) . The early trapping and growth of Lm appeared normal after PTx treatment because Lm colony-forming units (CFU) in PTx-treated and control mice were similar for up to 6 hr ( Figure 1G ), and the initial cellular distribution of Lm appeared unaffected by PTx (data not shown). At 24 hr after infection, when Lm proliferation takes place primarily in the PALS, the number of viable bacteria was markedly reduced ($90% decreased) compared with untreated mice ( Figure 1G) . Thus, the reduced number of bacteria in the PALS after PTx treatment is primarily due to inhibition of bacterial entry and not due to effects on Lm capture or growth during the early stage of infection.
Spleen Remodeling in Response to Lm Infection
We examined the distribution of host cells in the spleen before and after infection to identify the cell types that migrate to the PALS and possibly transport Lm. In uninfected mice, host cell populations were observed in their expected locations in the spleen ( Figure S3A ). At 12 hr, Lm colocalized with CD11b + cells in the PALS and CD11c + cells primarily near the bridging channel, a structure that connects the WP to the RP ( Figure 2A ; Metlay et al., 1990; Mitchell, 1973) . Metallophillic marginal zone macrophages (MOMA-1 + ) ( Figure 2A ; Kraal and Janse, 1986) had not entered the PALS in substantial numbers at this time. By 24 hr after infection, the number of MOMA-1 + , CD11b + , and CD11c + cells had increased in the PALS ( Figure S3B ). In contrast, F4/80 + (RP macrophages), MARCO + (Elomaa et al., 1995) , and ER-TR9 + (MZM) (Dijkstra et al., 1985) Figure 2B ). Bacteria were also found in MOMA-1 + ( Figure 2B , arrowhead) and CD11c + cells, although in lower numbers than observed for CD11b + cells.
Lm Entry into PALS Requires CD11c + Cells
To determine which cells are involved in Lm invasion of the PALS, we took advantage of the different recovery kinetics of splenic macrophages and DCs after clodronate-liposome-mediated depletion (van Rooijen et al., 1989) and looked for an association between host-cell recovery and Lm infection of the PALS. The injection of clodronate liposomes ablated splenic macrophages by day 2 after treatment and these cells remained depleted for at least 1 week ( Figure S4 ), as reported previously (van Rooijen et al., 1989) . In our hands, clodronate liposomes also depleted CD11c + cells by day 2, but these cells recovered substantially by day 6 ( Figure S4 ). Similar DC recovery kinetics were observed in work with the CD11c-DTR transgenic system (Jung et al., 2002) and is consistent with the high turn-over rate (3 days) reported for splenic CD11c + cells (Kamath et al., 2000) . Notably, CD11b + cells were not depleted by clodronate liposome treatment and appeared to slightly increase in number by day 2 ( Figure S4 ). The CD11b + cells identified in our sections are most likely granulocytes ($95% are F4/80 À and Gr-1 + , data not shown) and recently recruited inflammatory monocytes or tumor necrosis factor-alpha and inducible nitric oxide synthaseproducing DCs (TipDCs) (Serbina et al., 2003) .
To determine which cells play a role in the translocation of Lm to PALS, we depleted splenocytes with clodronate liposomes, then infected mice with Lm on either day 2 or 6 after clodronate 
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Antigen Presentation in Splenic White Pulp administration. The PALS was examined 24 hr later for the presence of Lm ( Figure 3A ). In mice infected on day 2, when both macrophages and CD11c cells were depleted, the vast majority of bacteria ($70%) were found in the MZ ( Figure 3B , left) and <10% of the total Lm signal was present in the PALS, compared to $70% in infected mock-depleted controls ( Figure 1B ). In mice infected on day 6 after clodronate treatment, when CD11c + cells had recovered but macrophages had not, widespread Lm growth in the PALS was observed ( Figure 3B , right), suggesting that DCs play an important role in the progression of Lm infection to the PALS. Because CD11b + cells are present on day 2 when Lm remains in the MZ, these cells do not play a dominant role in the initial entry of Lm into the PALS, but most likely follow the bacteria into the PALS once it becomes infected. The close association between DC appearance and PALS infection was confirmed by means of CD11c-DTR mice (Jung et al., 2002 ) and a similar cell depletion and recovery approach ( Figure S5 ).
The Arrival of Infected DCs in the PALS Initiates Antigen Presentation
The precise location of T cell priming in the spleen is unknown. T cells are most abundant in the PALS; however, they are also found in the RP and MZ and antigen presentation could occur in these compartments as well. Based on our depletion and recovery results, we speculated that the entry of infected DC into the PALS triggers antigen presentation to T cells.
To test this hypothesis, we used Lm-specific CD8 + T cells from WP11.12 TCR transgenic mice (Mercado et al., 2000; Wong and Pamer, 2003) to detect antigen presentation in situ. BALB/c mice received 4 3 10 6 adoptively transferred CFSE-labeled WP11.12 CD8 + T cells and cells were allowed to home (4-8 hr) before mice were infected with Lm. At various times after infection, spleen cryosections were examined by immunofluorescence microscopy for T cell clustering as evidence of antigen recognition ( Figure 4A ). In the absence of infection (0 hr), WP11.12 T cells were distributed evenly in the PALS area and appeared bright and small, consistent with a resting phenotype. As early as 9 hr after infection, many WP11.12 T cells clustered in the PALS near the bridging channel (9 hr, inset), indicating that antigen presentation had begun. At 21 hr after infection, clusters had increased in size and moved into the center of the PALS, and by 41 hr, T cells had dissociated and large activated CFSE lo WP11.12 T cells were distributed evenly through out the PALS (41 hr, inset). We could not detect WP11.12 T cell clusters in the MZ or RP over this time frame.
Infected CD11c + cells were often associated closely with WP11.12 T cell clusters ( Figure 4B , CD11c). These Lm-containing cells were MHC II + and showed characteristic DC morphology ( Figure 4B , MHCII). Although CD11b + cells were found near T cell clusters, they were not MHC II + and did not localize to the center of clusters (data not shown). Lm was typically observed in the center of T cell clusters in cryosections ( Figure 4B ) and in spleen explants via GFP-labeled bacteria and 2P microscopy ( Figure 4C ). We did not find T cell clusters associated with MARCO + or MOMA-1 + macrophages during the first 41 hr of infection (data not shown). Thus, DCs appear to be the primary APC type interacting with CD8 + T cells in the early stages of infection.
Lm Transport to PALS Is Required for Antigen Presentation
We performed time-lapse 2P microscopy (Germain et al., 2006; Miller et al., 2002) to determine whether blocking Lm entry into the PALS with PTx would inhibit antigen presentation. Spleens were removed, secured to plastic coverslips with veterinary tissue adhesive, cut longitudinally with a vibrotome to expose the white pulp regions, and placed in warm oxygenated medium for imaging. In uninfected mice, Lm-specific WP11.12 T cells moved randomly in the PALS with a median track velocity of $5 mm min À1 and a motility coefficient of $60 mm 2 min À1 , similar to polyclonal CD8 + T cells (Figures 5A and 5B; see also Movie S1).
T cells migrated randomly and did not form clusters, similar to the T cell behavior previously observed in lymph nodes (Miller et al., 2002) . However, the median T cell velocities measured in spleen explants were lower than mean values published for T cell migration in lymph nodes of $12 mm/min (Miller et al., 2002) . Our explanation for this discrepancy is that the decreased frame rate used in our current study ($2 images/min versus 4-6 images/min in previous studies) smoothes the characteristically large fluctuations in velocity associated with T cell motility and reduces the measured peak velocity in the data set. A decrease in peak velocity consequently yields a lower median velocity because the median is calculated from the velocity range. To investigate this issue further, we imaged T cells in explanted lymph nodes with our acquisition protocol and found slightly higher median T cell velocity ($7-8 mm/min, data not shown), suggesting that T cell motility is slightly slower in the spleen. In infected mice, WP11.12 T cells showed significantly reduced velocity and motility (Figures 5A and 5B; see also Movie S2). Lm-specific T cells formed large aggregates in the PALS containing approximately 15 cells per cluster (Figures 4C and 5B) . Occasionally, a few polyclonal CD8 + T cells interacted transiently with the WP11.12 clusters, but most remained motile with no substantial reduction in velocity and motility ( Figure 5B ), indicating that cluster formation is antigen specific. Because the high antigen-specific T cell frequencies in adoptive transfer experiments can alter the kinetics and differentiation of responding T cells, we performed a limited number of experiments by using as few as 500,000 adoptively transferred Lm-specific T cells ( Figure S6 ). Under these conditions we observed similar antigen recognition kinetics and clustering behavior ($4 cells per cluster; Figure S6 ; Movie S3).
When mice were pretreated with PTx to prevent Lm transport to the PALS, the clustering of bacteria-specific T cells was inhibited (Figures 5A and 5B; see also Movie S4). The lack of clustering was not due to the inhibition of T cell motility, because adoptively transferred polyclonal T cells moved with comparable velocity and motility in PTx-pretreated and untreated mice (Figures 5A and 5B) in our experimental protocol. When PTx was given $2 hr after T cell adoptive transfer, we observed decreased T cell motility (data not shown), similar to the results of 
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Antigen Presentation in Splenic White Pulp others (Huang et al., 2007) . This suggests that although PTx is capable of inhibiting T cell migration in the spleen, it does not remain active 24 hr after injection. As a further control for potential PTx effects on T cells, we administered PTx after Lm had entered the PALS (9-10 hr after infection). Lm-specific and polyclonal T cells were transferred and 2 hr later spleen explants were ex- Lm (a five times higher dose was used in this group in order to compensate for the reduced Lm burden in the PTxtreated mice). PTx reproducibly inhibited Lm-specific T cell proliferation but did not completely block it. The mean ± SD of three mice in one representative experiment is shown. Data are representative of at least three independent experiments with similar results.
amined by 2P microscopy. Once Lm transport had occurred, PTx treatment no longer inhibited WP11.12 cluster formation whereas control T cells showed normal motility (Movie S5). Although Lm could be detected in the MZ and RP of PTx-treated mice ( Figure 1D ), we did not detect T cell clusters in these regions (Figure 4 ; 2P data not shown).
As a second indicator of antigen presentation, we measured adoptively transferred WP11.12 T cell proliferation by CFSE dilution assay. PTx pretreatment reproducibly decreased the number of proliferating WP11.12 T cells compared to untreated controls ( Figure 5C ). Decreased T cell proliferation was also observed when a larger inoculum of Lm was used to compensate for the lower Lm CFU present in PTx-treated mice at 24 hr ( Figure 5C , bottom). We also assessed the effects of PTx treatment on antigen presentation in vitro by using the Ova-specific OT1 transgenic T cells. DC were isolated from spleen and treated in vitro with 20 and 200 ng/ml Ptx for 2 hr (200 ng/ml is roughly equivalent to the in vivo dose of 500 ng per mouse.). After PTx treatment, DC were fed OVA or OVA-conjugated beads in the presence of LPS for 4 hr before coculture Immunity Antigen Presentation in Splenic White Pulp with OT1 T cells for 3 days. Ptx had no detectable effect on antigen presentation with either OVA or OVA-conjugated beads ( Figure S7 ).
Next, we examined the effect of PTx treatment on the behavior of resident DCs and macrophages by using 2P microscopy. CD11c-YFP mice (Lindquist et al., 2004) were given a single i.p. injection of PTx (500 ng) 1 day before the spleens were harvested and prepared for time-lapse imaging. Fluorescent beads were injected i.v. to define the MZ and distinguish YFP + MZMs (containing many beads) from DCs (containing few or none) in our analysis. In mock-treated mice, DCs showed active probing behavior and appeared to migrate randomly in the PALS and bridging channel with a median velocity of 6.3 mm/min (Movie S6 and Figure 6 ). We also observed DCs migrating to and from the MZ-PALS border. In Ptx-treated mice, DC probing behavior was lost and cell velocity was significantly reduced (p < 0.001, Movie S7 and Figure 6A ). Although DCs were able to move slightly, they exhibited little displacement over time and their motility coefficient was significantly reduced (p < 0.001, Figure 6B ). PTx treatment did not appear to alter the behavior of MZMs and these cells remained essentially nonmotile over the time frame of our imaging experiments (Movies S6 and S7 and Figure 6 ). During sublethal Lm infection, T cell responses reduce the bacterial burden 5-7 days after challenge and over 2 weeks, resulting in the eradication of Lm. We tested whether blocking Lm entry to the PALS with PTx affected the survival of mice to primary infection. Although PTx-treated mice had reduced CFU in the spleen at 24 hr ( Figure 1E ), these mice could not control Lm at later times and succumbed to infection (Figure 7 ). Because endogenous lymphocytes are presumably exposed to PTx in these experiments, it is unclear whether PTx affects survival by inhibiting antigen presentation to CD8 + T cells or by inhibiting cell effector functions. Moreover, the decreased survival of PTx-treated mice could be due to the defective recruitment of TipDCs, which have been shown to be required to control Lm infection (Serbina et al., 2003) .
DISCUSSION
In this study, we sought to determine whether DCs play a role in transporting bacteria from the MZ to the PALS, analogous to their role in carrying antigens from peripheral tissues to draining lymph nodes. The location and kinetics of bacterial antigen presentation in the spleen are poorly defined. 2P microscopy allowed us to assess antigen presentation in situ by quantifying changes in the motility and clustering of Lm-specific T cells. In the Lm infection model, we did not find evidence of bacteria-specific CD8 + T cell responses in either the MZ or RP during the first 2 days of infection, suggesting that the PALS is the primary compartment where CD8 + T cells first recognize antigen. In our study, we focused on the earliest detectable stages of antigen presentation. However, work with MHC class I tetramer staining in situ 
. PTx Effects on DC and Macrophage Motility In Situ
Spleen explants were prepared (as described in Experimental Procedures) from CD11c-YFP mice (Lindquist et al., 2004) 
Figure 7. PTx Treatment Decreases the Survival of Mice after Lm Infection
Mice were pretreated with PTx i.p. then challenged with 5 3 10 3 Lm EGD.
Survival was followed for 21 days. p values were calculated with a log rank test (n = 10 mice per group). Black line, infected mice; red line, PTx-treated, infected mice; blue line, PTx-treated, uninfected mice. Ptx treatment severely compromised the host responses to Lm infection.
showed that CD8 + T cells clustered at the T cell-B cell zone border and MZ beginning 3 days after infection (Khanna et al., 2007) , suggesting that other regions of the spleen are involved at later times. Moreover, T cell responses were detected in the splenic RP after an i.v. injection of soluble peptide (Odoardi et al., 2007) , demonstrating that antigen presentation can occur outside the PALS. To what extent immune responses to viruses and other bacteria are initiated in distinct splenic compartments is an interesting question. If the location of antigen presentation is dependent on the type and route of infection, then the tissue microenvironment where antigen presentation occurs might play a pivotal role in shaping the character of the pathogen-specific immune response.
Our primary evidence linking Lm transport to antigen presentation is that PTx treatment inhibits both the entry of bacteria into the PALS and the recognition of bacterial antigen. We used 2P imaging to analyze Lm-specific T cell responses and found that PTx inhibited the clustering and arrest of T cells only if administered before Lm gained entry into the PALS. We found that PTx treatment after T cell adoptive transfer does indeed decrease T cell velocity in the spleen, as observed by others (Huang et al., 2007; Okada and Cyster, 2007) . However, in our protocol, the inhibition of antigen presentation by PTx is due to blocking APC migration and not due to inhibition of T cell motility, because adoptively transferred T cells appear unaffected (i.e., motility was identical in PTx-treated and untreated mice). Moreover, when we gave PTx 2 hr before T cell transfer, control T cells showed normal motility and Lm-specific T cells clustered normally. Our explanation is that PTx is rapidly consumed in vivo and does not affect T cells transferred subsequently.
Our 2P microscopy experiments revealed that PTx markedly inhibited DC motility in the spleen. Previously, PTx was reported to inhibit DC homing to the thymus, but not the spleen (Bonasio et al., 2006) . Although DCs may enter the spleen passively from the circulation, DC migration into the PALS appears to require chemokine receptor signaling, as suggested by studies with CCR7-deficient knockout mice (Kursar et al., 2005) .
There were no statistical differences in CFU counts per spleen between Ptx-treated mice and untreated controls during the first 6 hr of infection, suggesting that PTx treatment did not interfere with the initial trapping of Lm. However, the increased CFUs in PTx-treated mice at 24 hr indicated that the infection does not progress normally and that Lm proliferation in the PALS is inhibited. Although PTx could interfere with actin rearrangements involved in the host cell invasion by Lm or cell-cell spread, we believe that the main effect of PTx is on splenocyte migration because others have shown that ActA-deficient Lm were capable of invading and proliferating in the PALS, albeit at a lower level (Muraille et al., 2005) . Moreover, we performed histological experiments to examine the impact of PTx pretreatment on Lm capture and found that the cellular distribution and amount of bacteria captured was similar to untreated control mice. Neuenhahn et al. (2006) concluded that viable Lm was found exclusively in CD8a + DCs 3 hr after infection and proposed that these DCs were responsible for the initial trapping of live Lm in the spleen. Our results extend on previous work by showing that DCs facilitate Lm entry into the PALS and that this entry is required for efficient antigen presentation. It is noteworthy that we found infected MOMA-1 + macrophages and CD11b + cells in the PALS at 24 hr, but did not find CD8 + T cell clusters associated with these cells, and therefore their role in antigen presentation remains unclear. A variety of splenic phagocytes capture Lm initially, but bacteria expand transiently in DCs, suggesting that DCs may support Lm growth in vivo (unpublished observations). It is possible that the transient proliferation of bacteria in DCs is advantageous to host survival because it would be expected to provide abundant cytosolic antigen to stimulate CD8 + T cell-mediated immunity.
The role of different DC subsets in Lm pathogenesis and antigen presentation is a key question that is difficult to address because current methods for DC ablation, such as the CD11c-DTR system, deplete all CD11c + DCs, as well as splenic macrophages (Probst et al., 2005) . The spleen contains two main DCs subsets, CD8a + DEC205 + DCs, which reside in the PALS and bridging channel (Steinman et al., 1997) and present MHC I bound peptides more efficiently (Dudziak et al., 2007) , and CD8a À , 33D1 + DCs found primarily in the RP and MZ (Steinman et al., 1997) , which present antigen to CD4 + T cells preferentially. Neuenhahn et al. (2006) observed CD8a + DCs in the MZ and RP where they would have direct contact with Lm entering the spleen. Although CD8a + DCs were shown to preferentially contain live Lm, DCs were not strictly required for antigen presentation because the adoptive transfer of infected macrophages could restore T cell responses in mice depleted of DCs (Neuenhahn et al., 2006) . CD8a + DC have been shown to prime T cell responses to Lm (Belz et al., 2005) , suggesting that these DCs play a central role in stimulating Lm-specific responses. Moreover, CD8a + DCs are specialized for crosspresentation (den Haan et al., 2000) and this function may be important for stimulating T cell responses to Lm. In our study it is noteworthy that we often found T cell clusters around infected DCs, suggesting that early CD8 + T cell activation proceeds primarily via the classical MHC I pathway. We did not examine MHC II antigen presentation and it is entirely possible that different regions of the spleen and distinct APCs might be involved in activating CD4 + T cells (Odoardi et al., 2007) . Defining the precise cellular mechanisims that deliver bacterial antigens to the PALS is important for understanding how antigen presentation occurs in the spleen. Recently, Cinamon et al. (2008) showed that MZ B cells shuttle soluble antigen from the MZ to follicles in the white pulp in a CXCR5-dependent manner. Because the entry of Lm into the PALS is sensitive to PTx treatment, bacterial transport likely involves chemokine signaling as well. CCR7-deficient mice showed decreased T cell priming and increased susceptibility to Lm infection (Kursar et al., 2005) . This result was attributed to the failure of T cells and DCs to efficiently colocalize in the absence of CCR7; however, this study did not address the impact of CCR7 deficiency on Lm transport and antigen presentation directly. The work of others suggests that the transport of Lm to the PALS is contingent on the cytosolic entry of bacteria given that neither heatkilled nor LLO-deficient Lm enter the host cell cytosol and both fail to reach the PALS after i.v. challenge (Glomski et al., 2003; Lauvau et al., 2001; Muraille et al., 2005) . Importantly, these noncytosolic forms of Lm also fail to elicit robust T cell immunity, suggesting a link between PALS infection and T cell priming. As suggested by Muraille et al. (2005) , a critical step in the progression of Lm infection to the PALS might be the recognition of bacteria by intracellular sensors such as the NOD-like receptors (Mariathasan and Monack, 2007; Dufner et al., 2007; Park et al., 2007) .
There are several plausible mechanisms for Lm entry to the PALS: migration of infected DCs from MZ to PALS, migration of PALS DCs to the MZ boundary to capture and carry back Lm, and cell-cell spread of Lm from MZ to PALS. The issue of cell-cell spread has been addressed by experiments with ActA-deficient Lm, which cannot mobilize host cell actin (Muraille et al., 2005) . In the presence of gentamicin, ActA-deficient Lm can still enter the PALS, arguing that PALS infection does not require cell-cell spread. Ideally, single-cell tracking experiments with GFP-Lm and 2P microscopy will help determine whether one or more of these mechanisms is at work.
We propose that early host-pathogen interactions in the MZ lead to the transport of intracellular antigen to the PALS for presentation to T cells. Our results with Lm suggest that targeting antigen delivery to the PALS might be an effective strategy to enhance vaccine efficacy and the priming of CD8 + T cells to intracellular pathogens.
EXPERIMENTAL PROCEDURES
Mice BALB/cJ mice were obtained from The Jackson Laboratory. CD11c-YFP mice (Lindquist et al., 2004) were a gift of the M. Nussenzweig lab. WP11.12 TCR transgenic mice, expressing a transgenic TCR that recognizes p60 [449] [450] [451] [452] [453] [454] [455] [456] [457] peptide in the context of H-2K d (Mercado et al., 2000) , were a gift from E. Pamer (Sloan-Kettering Institute, NY). Mice were maintained and bred under SPF conditions in the Washington University mouse facility.
Bacteria, Fluorescent Beads, and Dextran
The GFP-expressing Lm EGD strain was made with the pNF8 vector (Fortinea et al., 2000) . The LD 50 of our GFP-expressing Lm strain was 1.1 3 10 5 in BALB/ c mice, or $50-fold attenuated compared with wild-type EGD. Both GFP-expressing Lm and the EGD strain were stored as frozen glycerol stocks ($1 3 10 9 /ml) at À80 C. Mice were infected with Lm diluted in PBS (to indicated doses) from frozen stocks or overnight cultures. For infection times less than or equal to 2 hr, we typically used 10 7 EGD Lm. For infections at 12 and 24 hr, we used 10 4 -10 5 bacteria. FluoSpheres carboxylate-modified microspheres (yellow-green, 1.0 mm and 0.5 mm) and Fluorescein-conjugated dextran (lysine-fixable, 500 kD) were purchased from Invitrogen. All reagents were injected i.v. in a volume of 200 ml.
Histology
Mice were euthanized and spleens harvested and embedded in Tissue-Tek OCT compound. 5 mm cryosections were cut and fixed with 4% paraformaldehyde in PBS (pH 7.2) at 4 C for 5 min and then blocked with StartingBlock Blocking Buffer (PIERCE) for 10 min before being sequentially incubated with fluorescent dye-conjugated or biotin-conjugated primary antibodies (1:100 dilution with blocking buffer), fluorescent dye-conjugated secondary antibodies and/or fluorescent dye-conjugated streptavidin (1:100 dilution with blocking buffer). Sections were mounted in GVA mount (Invitrogen) and stored at 4 C. Details for antibodies and reagents used for immunofluorescence staining can be found in the Supplemental Data.
Immunofluorescence Microscopy Four-color fluorescence microscopy of cryosections was performed with an Olympus BX51 equipped with 100W mercury lamp (Olympus) and a SPOT RT CCD camera (Diagnostic Instruments). Monochrome images (1200 pix 3 1600 pix = 885 3 1180 mm with 103 objective; 440 3 586 mm with 203 objective, 12-bit depth) were acquired through fluorescence filters optimized for DAPI, FITC, TRITC, and Cy5 (Chroma). Images were acquired, processed to reduce background, pseudo-colored, and merged with SPOT RT camera software. Immunofluorescence images were segmented into splenic compartments and the number of pixels specific for Lm staining or fluorescent beads was measured and expressed as the percentage of pixels in each compartment (see Supplemental Data for details).
Pertussis Toxin and Clodronate Liposome Treatment
PTx was purchased from Sigma (St. Louis, MO). Mice were injected with 500 ng of PTx i.p. 1 day prior to infection (10 7 for 0.5 hr and 10 5 for 24 hr) and Lm tissue distribution was assessed by immunofluorescence at 0.5 and 24 hr later.
In other experiments, the survival of PTx-treated mice after Lm infection with 10 3 CFU of EGD (LD 50 $2 3 10 3 in BALB/C mice) was determined. In 2P experiments, mice were given 500 ng PTx i.p. 1 day before to the transfer of fluorescently labeled Lm-specific and polyclonal T cells. T cells were allowed to home for several hours and then mice were infected by an i.v. injection of Lm (10 4 for EGD or 10 5 GFP-Lm). Approximately 9 hr later, spleen explants were cut and imaged with 2P microscopy and T cell behaviors (velocity and clustering) analyzed. In some experiments, PTx was administered 8-9 hr after infection to allow Lm time to enter the PALS. T cells were adoptively transferred 1-2 hr later and T cell behaviors analyzed with 2P microscopy for changes in motility and clustering beginning at $2 hr after T cell transfer. For depletion of phagocytes, clodronate liposome suspensions were prepared as described previously (Calderon et al., 2006; van Rooijen and van Kesteren-Hendrikx, 2003) . Mice were given 200 ml of clodronate liposome suspension i.v. 2 or 6 days before infection. The depletion of macrophages and dendritic cells was assessed on day 2 and day 6 by staining sections for MARCO, MOMA-1, CD11b, and CD11c. Spleens were examined by immunofluorescence microscopy 24 hr after infection to quantify the amount of Lm in the MZ, RP, and PALS regions. Similar depletion and recovery experiments were preformed with the CD11c-DTR system of Jung et al. (Jung et al., 2002; Probst et al., 2005) .
Two-Photon Microscopy
CD8
+ T cells were purified by negative selection with magnetic beads (Miltenyi Biotec) from BALB/cJ or WP11.12 mice (Mercado et al., 2000) , then labeled for 30 min at 37 C with 20-50 mM CMAC, 10 mM CFSE, or 10 mM CMTMR (Invitrogen). T cells (5 3 10 5 -7 3 10 6 ) were resuspended in 200 ml of PBS, adoptively transferred by tail vein injection and allowed to home for several hours before mice were infected with 10 5 EGD Lm. In some experiments, we infected mice with 10 6 GFP-expressing Lm to localize bacteria and T cell clusters in 3D
space. Explanted spleens were secured to coverslips with a thin film of VetBond (3M). To image the WP, spleens were cut longitudinally with a vibratome (Pelco). Spleen sections were placed in a flow chamber and maintained at 37 C by perfusion with warm, high-glucose DMEM bubbled with a mixture of 95% O 2 and 5% CO 2 . Time-lapse imaging was performed with a custombuilt two-photon microscope, fitted with two Chameleon Ti:sapphire lasers (Coherent) and an Olympus XLUMPlanFI 203 objective (water immersed; numerical aperture, 0.95) and controlled and acquired with ImageWarp (A&B software). For imaging of GFP, the excitation wavelength was 890-915 nm; for CMTMR and CMAC, 780-800 nm was used. Signals from fluorescent dyes and GFP were separated by dichroic mirrors (490 nm, 515 nm, and 560 nm). To create time-lapse sequences, we typically scanned volumes of tissue 100 3 120 3 75 mm with 31 Z-steps of 2.5 mm each at 30-45 s intervals for up to 60 min.
CFSE T Cell Proliferation Assay
Purified 5-7 3 10 6 WP11.12 T cells were labeled with CFSE (5 mM) and transferred to recipient mice 2 hr before Lm infection (10 4 ). PTx-treated mice were given 500 ng of PTx i.p. 24 hr prior to infection with Lm (10 4 and 5 3 10 4 ). Beginning at 24 hr after infection, mice were given ampicillin (5 mg/ml in drinking water) to eliminate bacteria. On day 3 of infection, CFSE dilution was assessed by flow cytometry (2 3 10 6 cells) with Vb8.1 to enrich for WP11.12 T cells in the analysis.
Data Analysis
Cells were detected based on fluorescence intensity and cell tracks obtained with Volocity (Improvision) or Imaris (Bitplane) software. Tracks greater than 3 min (R7 time points) were included in the analysis. Cell velocities were reported as the median of instantaneous velocities in each cell track. Motility coefficients (mm 2 min À1 ) were calculated for individual tracks by linear regression of displacement 2 versus time plots with T Cell Analysis (John Dempster, University of Strathclyde). Clusters were analyzed in five randomly selected time points with PicViewer (John Dempster, University of Strathclyde) as previously described (Zinselmeyer et al., 2005) .
Statistical Analysis
Non-normally distributed data were presented as medians and compared with the Mann-Whitney U-test (two groups) or with an ANOVA followed by a suitable multiple comparison procedure (Dunn's or Dunnett's test).
SUPPLEMENTAL DATA
Supplemental Data include eight figures and seven movies and can be found with this article online at http://www.immunity.com/cgi/content/full/29/3/476/ DC1/.
